Integrated clinical and basic studies related to circumventing non-small cell lung cancer drug resistance.

[1]  S. Steinberg,et al.  Individualized chemotherapy for patients with non-small cell lung cancer determined by prospective identification of neuroendocrine markers and in vitro drug sensitivity testing. , 1993, Cancer research.

[2]  E. Holmes Postoperative chemotherapy for non-small-cell lung cancer. , 1993, Chest.

[3]  S. Steinberg,et al.  Peripheral airway cell marker expression in non-small cell lung carcinoma. Association with distinct clinicopathologic features. , 1992, American journal of clinical pathology.

[4]  G. Giaccone,et al.  Association between histological type and neuroendocrine differentiation on drug sensitivity of lung cancer cell lines. , 1992, Journal of the National Cancer Institute. Monographs.

[5]  S. Steinberg,et al.  p53 gene mutations in non-small-cell lung cancer cell lines and their correlation with the presence of ras mutations and clinical features. , 1992, Oncogene.

[6]  H. Garewal,et al.  UC Irvine UC Irvine Previously Published Works Title Retinoids and carotenoids in the prevention of oral cancer : a critical appraisal , 2005 .

[7]  M. Fukuoka,et al.  Establishment of tumor cell lines as an independent prognostic factor for survival time in patients with small-cell lung cancer. , 1991, Journal of the National Cancer Institute.

[8]  S. Steinberg,et al.  ras gene mutations in non-small cell lung cancers are associated with shortened survival irrespective of treatment intent. , 1991, Cancer research.

[9]  J. Levy,et al.  Photodynamic killing of human squamous cell carcinoma cells using a monoclonal antibody-photosensitizer conjugate. , 1991, Journal of the National Cancer Institute.

[10]  J. Minna,et al.  Mutations of ras genes distinguish a subset of non-small-cell lung cancer cell lines from small-cell lung cancer cell lines. , 1991, Oncogene.

[11]  S. Steinberg,et al.  Nonrandom structural and numerical chromosome changes in non‐small‐cell lung cancer , 1991, Genes, chromosomes & cancer.

[12]  J. Mulshine,et al.  Lung cancer: rational strategies for early detection and intervention. , 1991, Oncology.

[13]  J. Roth,et al.  Photodynamic therapy of oncogene-transformed cells. , 1991, The Journal of thoracic and cardiovascular surgery.

[14]  A. Gazdar,et al.  Tumor cell lines established in vitro: an independent prognostic factor for survival in non-small-cell lung cancer. , 1990, Annals of internal medicine.

[15]  L J Peters,et al.  Prevention of second primary tumors with isotretinoin in squamous-cell carcinoma of the head and neck. , 1990, The New England journal of medicine.

[16]  G. Giaccone,et al.  Reconstituted basement membrane (matrigel) and laminin can enhance the tumorigenicity and the drug resistance of small cell lung cancer cell lines. , 1990, Proceedings of the National Academy of Sciences of the United States of America.

[17]  E. Dmitrovsky,et al.  A Phase II Trial of Carboplatin (CBDCA) in Small‐Cell and Non‐Small‐Cell Lung Cancer with Correlation to In Vitro Analysis of Cytotoxicity , 1990, American journal of clinical oncology.

[18]  C. Boone,et al.  Identification of candidate cancer chemopreventive agents and their evaluation in animal models and human clinical trials: a review. , 1990, Cancer research.

[19]  I. Pastan,et al.  MDR1 gene expression in lung cancer. , 1989, Journal of the National Cancer Institute.

[20]  S. Steinberg,et al.  Lack of in vitro synergy between etoposide and cis-diamminedichloroplatinum(II). , 1989, Cancer research.

[21]  S. Steinberg,et al.  Neuroendocrine differentiation in endocrine and nonendocrine lung carcinomas. , 1988, American journal of clinical pathology.

[22]  S. Rodenhuis,et al.  Incidence and possible clinical significance of K-ras oncogene activation in adenocarcinoma of the human lung. , 1988, Cancer research.

[23]  A. Gazdar,et al.  The pathology of lung cancer--changing concepts and newer diagnostic techniques. , 1988, Seminars in oncology.

[24]  M. Sklar Increased resistance to cis-diamminedichloroplatinum(II) in NIH 3T3 cells transformed by ras oncogenes. , 1988, Cancer research.

[25]  S. Rodenhuis,et al.  Mutational activation of the K-ras oncogene. A possible pathogenetic factor in adenocarcinoma of the lung. , 1987, The New England journal of medicine.

[26]  J. Mulshine,et al.  Treatment of non-small-cell lung cancer. , 1986, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[27]  J. Battey,et al.  Changes in the phenotype of human small cell lung cancer cell lines after transfection and expression of the c-myc proto-oncogene. , 1986, The Journal of clinical investigation.

[28]  Griswold Dp Body burden of cancer in relationship to therapeutic outcome: consideration of preclinical evidence. , 1986 .

[29]  H. Kleinman,et al.  Role of collagenous matrices in the adhesion and growth of cells , 1981, The Journal of cell biology.

[30]  R C Young,et al.  Combination versus single agent chemotherapy: A review of the basis for selection of drug treatment of cancer , 1975, Cancer.

[31]  D. Slaughter,et al.  “Field cancerization” in oral stratified squamous epithelium. Clinical implications of multicentric origin , 1953, Cancer.